



2020

A

55,000.00

| | | | |
|---|--|------------------|------------------|
| | | | |
| 1 | | 31,301.88 | 26,500.00 |
| 2 | | 15,000.00 | 12,500.00 |
| 3 | | 16,000.00 | 16,000.00 |
| | | 62,301.88 | 55,000.00 |

1

2

3.22

/ 21.45 /

2

3.13

| | | | |
|----------|------------------|------------------|-------------|
| | | | |
| 1 | 30,101.88 | 26,500.00 | 96.17% |
| 1.1 | 27,855.35 | 26,500.00 | 88.99% |
| 1.1.1 | 15,266.42 | 14,500.00 | 48.77% |
| 1.1.2 | 12,588.93 | 12,000.00 | 40.22% |
| 1.2 | 1,446.52 | - | 4.62% |
| 1.3 | 800.00 | - | 2.56% |
| 2 | 1,200.00 | - | 3.83% |
| 3 | 31,301.88 | 26,500.00 | 100% |

31,301.88

26,500.00

2

1

2018

20

2

HBV

7,000

2

CHB

2,000 3,000

HCV

1,000

90%

3

3

7,000

2,000

3,000

2011

68.81

2015

| | | | | |
|------|------------|-------|-----------|-------|
| WHO | 2015 | 7,100 | | 39.9 |
| HCV | | | | 1,000 |
| | 2012 | 20.16 | 2018 | 21.94 |
| | | | 25% | 20% |
| 3% | | | | 10% |
| WHO | 2016 | 2030 | | |
| | | | PR | |
| | PegIFN | | RBV | DAAs |
| 2017 | DAAs | | | |
| | PR | | | |
| | DAAs | | | DAAs |
| | DAAs | | | DAAs |
| | 90% | | | |
| 12 | | | DAAs | |
| | DAAs | 50% | | |
| | IQVIAMIDAS | 2018 | DAAs | 166 |
| | | | | DAAs |
| | | 2014 | | |
| | | | 2017-2020 | 2020 |
| | HCV | | 100% | |
| | -HCV | | | |

2019 8 30
2020 12 31

cGMP 5 PDE5
2 cGMP

ED

ED

2015

ED

6.97%

ED

ED

80%

2014

2018

ED

28.5

60%

ED

50

ED

ED

ED

2019 7 30
2020 12 31

2

3

7,533.25

11,396.54

7,004.78

80

4

3.13 2
37,441.02 5,462.80

5

1

2

| | | |
|--|--|--------------|
| | | |
| | | 2019 J070028 |
| | | 2020 1 |
| | | 2020 H020004 |
| | | 2020 34 |

1

2.5

10 /

1 /

2.5

1.50

| | | | |
|----------|------------------|------------------|----------------|
| | | | |
| 1 | 14,427.03 | 12,500.00 | 96.18% |
| 1.1 | 13,273.22 | 12,500.00 | 88.49% |
| 1.1.1 | 7,344.09 | 7,000.00 | 48.96% |
| 1.1.2 | 5,929.13 | 5,500.00 | 39.53% |
| 1.2 | 825.99 | - | 5.51% |
| 1.3 | 327.82 | - | 2.19% |
| 2 | 572.97 | - | 3.82% |
| 3 | 15,000.00 | 12,500.00 | 100.00% |

15,000.00

12,500.00

2

1

2030

2020

15,823

15%

29.26%

33.26%

2

3

15-64
2030 60 30%

3

1

10,000

| | | | |
|------|----|------|--------|
| | | | Lancet |
| 2020 | 1 | 1-20 | 99 |
| | 43 | | 1 |

2018 1.2

2018 330

2

3

2017 1,004 2018
1,234 20% 2019
1,500

4

1.50 2.5
42,345.38 3,370.07

5

1

2

| | |
|--|----------|
| | |
| | 2019 260 |
| | 2019 72 |

1

16,000

29.09% 30%

2

1

2019

7,533.25 11,396.54 7,004.78

25.44% 28.32% 16.88%

2019 7 9 c-MET GST-HG161 I

FACO

2020

A

2020 4 1